Replies to post #162156 on Innovation Pharmaceuticals Inc (IPIX)

[TheHound]

Prurisol (Ph2b) has the potential to be the next best or better oral drug option for Psoriasis. Celgene’s OTEZLA (apremilast) oral drug for Psoriasis was approved in 2014 and is on its way to achieve $1 billion in sales within three years of launch. Prurisol (abacavir glycolate), an ester of abacavir (Figure 8), is being developed under advantages of a 505(b)(2) registration approach for the treatment of psoriasis with the advantage of an established data base of safety of Ziagen (reference drug abacavir sulphate) approved since 1998 for HIV. Prurisol could outpace competing oral drugs in the pipeline as well as other drug candidates in the Cellceutix pipeline as no long term safety studies will be required as it is using Ziagen as the reference drug. As a new salt form it will be approved as a NCE and not a “me too” drug with strong Intellectual Property (IP) and patent protections.

http://cellceutix.com/cellceutix-releases-pharmacokinetics-data-from-phase-2-trial-of-prurisol-for-treating-psoriasis-data-complements-efficacy-data-reported-last-week/

http://cellceutix.com/cellceutix-corporation-announces-industry-veteran-arthur-p-bertolino-md-phd-mba-joins-company-as-president-and-chief-medical-officer/

http://cellceutix.com/cellceutix-to-initiate-phase-2b-trial-of-prurisol-for-chronic-plaque-psoriasis/

http://www.mpadvisor.com/xyz/Cellceutix_160826.pdf